Director Hsu Feng-Lin reports 3,000 Jyong Biotech (MENS) shares on Form 3

Rhea-AI Filing Summary

Jyong Biotech Ltd. director Hsu Feng-Lin has reported initial ownership of the company’s shares. The Form 3 filing lists 3,000 shares of Common Stock held with direct ownership. This is a baseline disclosure of holdings and does not reflect a new purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hsu Feng-Lin

Role Director

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 3,000 shares (Direct)

Footnotes (1)

Key Figures

Common Stock held: 3,000 shares

1 metrics

Common Stock held 3,000 shares Shares of Jyong Biotech Common Stock directly owned after reported position

Key Terms

Form 3, Common Stock, direct ownership

3 terms

Form 3 regulatory

"The Form 3 filing lists 3,000 shares of Common Stock"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Common Stock financial

"lists 3,000 shares of Common Stock held with direct ownership"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

direct ownership financial

"held with direct ownership"

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hsu Feng-Lin

(Last) (First) (Middle)

23F-3, NO.95, SEC. 1, XINTAI 5TH RD.

(Street)

NEW TAIPEI CITY TAIWAN, PROVINCE OF CHINA 221

(City) (State) (Zip)

TAIWAN

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2026

3. Issuer Name and Ticker or Trading Symbol
Jyong Biotech Ltd. [ MENS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Hsu Feng-Lin	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Jyong Biotech (MENS) disclose in this Form 3 filing?

The filing shows director Hsu Feng-Lin reporting beneficial ownership of 3,000 shares of Common Stock. This is an initial ownership statement, establishing the director’s equity position when they became subject to reporting rules.

How many Jyong Biotech (MENS) shares does Hsu Feng-Lin hold?

Hsu Feng-Lin is reported as holding 3,000 shares of Jyong Biotech Common Stock following the reported position. These shares are listed as directly owned and represent the director’s baseline stake at the time of this Form 3.

Does this Jyong Biotech (MENS) Form 3 show any insider buying or selling?

No insider trade is reported; the Form 3 records holdings rather than a transaction. It shows 3,000 Common Stock shares owned directly after the reported date, serving as an initial snapshot of the director’s position.

Is the Jyong Biotech (MENS) ownership held directly or indirectly by Hsu Feng-Lin?

The Form 3 identifies the 3,000 Jyong Biotech Common Stock shares as directly owned, using ownership code “D.” No trusts, entities, or indirect ownership structures are indicated in the provided data for this position.

Are there any derivative securities reported for Jyong Biotech (MENS) in this Form 3?

The data shows no listed derivative positions for Hsu Feng-Lin. Only 3,000 shares of Common Stock are reported, and the derivative summary is empty, indicating no options or similar derivative holdings in this disclosure.